Document:

<PAGE>

                                                                   Exhibit 10.29

                                 First Amendment

With reference to the License Agreement dated the 3rd day of November, 2006 (the
"Execution Date") entered into by and between Novartis Pharma AG (referred to as
"Novartis"), a corporation organized and existing under the laws of the
Switzerland and having its principal offices at Lichtstrasse 35, CH-4056 Basel,
Switzerland and Molecular Insight Pharmaceuticals Inc., a corporation organized
and existing under the laws of Delaware, with an office at 160 Second Street,
Cambridge, MA 02142 USA (hereinafter "MIP"); MIP and Novartis hereby enter into
this First Amendment to amend the License Agreement as follows:

1.   IN SECTION 2.4.1 OF THE LICENSE AGREEMENT, A NEW PARAGRAPH 2.4.1.B SHALL BE
     ADDED. THE SECTION 2.4 SHALL NOW READ:

     2.4.1.a) Novartis undertakes to physically transfer the content of its
     investigational new drug application in the United States or equivalent
     documents for other countries, and all related amendments, correspondence,
     meeting minutes and any other documents (hereinafter collectively referred
     to as "IND") upon the effective date of this Agreement. For the avoidance
     of doubt, this does not include those parts of the IND Controlled by MMI or
     any information related to the manufacture of the Tyr-3 octreotide.
     (UNCHANGED)

     2.4.1 b) Novartis will provide a drug substance Drug Master File (DMF) to
     the FDA by May 2007 in support of a proposed June 2007 submission by
     Molecular Insight Pharmaceuticals.

2.   EXHIBIT 3:

     The Exhibit 3 attached to the License Agreement shall be replaced by the
     Exhibit 3 attached hereto as Annex 1.

3.   EFFECTIVE DATE

3.1  This Amendment shall become retroactively effective at the Effective Date,
     as defined in the License Agreement, and shall remain effective until the
     expiration or termination of the License Agreement.

4.   ENTIRE AGREEMENT

4.1  This Amendment intends to amend the License Agreement to the extent
     provided hereunder. The License Agreement as modified by this Amendment
     shall constitute the entire agreement between the parties hereto with
     respect to the subject matter hereof and shall supersede, cancel and annul
     any prior written or oral agreements.

4.2  Except for the terms and conditions amended in this Amendment, all other
     terms and conditions of the License Agreement and its related agreements
     shall remain in full force and effect.

5.   TITLES

5.1  Titles in this Amendment have been inserted for convenience only and shall
     in no way be used in the interpretation hereof.

<PAGE>

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the dates
indicated below.

MOLECULAR INSIGHT CORPORATION           NOVARTIS PHARMA AG

Date: December 21, 2006                 Date: 04 January 2007

By: /s/ David Barlow                    By: /s/ Jean-Marc Sequier
    ---------------------------------       ------------------------------------
Name/title: Chairman & Chief            Name/title: Jean-Marc Sequier
            Executive Officer

                                        By: /s/ Emmanuelle Ferrari
                                            ------------------------------------
                                        Name/title: Emmanuelle Ferrari
                                                    Legal Counsel

                                                                               2

<PAGE>

                                     ANNEX 1

                                    EXHIBIT 3

   ADDENDUM TO THE LICENSE AGREEMENT BETWEEN NOVARTIS PHARMA AG AND MOLECULAR
                          INSIGHT PHARMACEUTICALS INC.

Upon execution of the Krenning License, this Addendum by and between Novartis
Pharma AG (referred to as "Novartis"), a corporation organized and existing
under the laws of the Switzerland and having its principal offices at
Lichtstrasse 35, CH-4056 Basel, Switzerland, and Molecular Insight
Pharmaceuticals Inc., a corporation organized and existing under the laws of
Delaware, with an office at 160 Second Street, Cambridge, MA 02142 USA
(hereinafter "MIP") shall become immediately and automatically effective
("Effective Date").

WHEREAS, Dr. Krenning, Professor Dr. S.W.J. Lamberts ("Lamberts") and Sandoz
Pharma Ltd ("Sandoz") have made joint inventions relating to labelled
somatostatin analogues covered in the Patent Case 100-7382 and 118-7595
(hereinafter the "Generic Patent"), as set out on Exhibit 1a of the License
Agreement;

WHEREAS, Krenning, Lamberts and Sandoz entered into a contractual relationship
dated 10 October 1989 (the "Letter Agreement") under which Krenning granted
Sandoz exclusivity to the Generic Patent in return of a royalty to be determined
within a subsequent agreement ("Krenning License");

WHEREAS, Novartis Pharma AG is the successor to the rights and obligations of
Sandoz;

WHEREAS, Novartis and Krenning have now executed the Krenning License;

WHEREAS, Novartis and MIP have entered into a license agreement (hereinafter the
"License Agreement") under which MIP as granted a non-exclusive license to the
Generic Patent to develop, sale and promote the Product;

WHEREAS, MIP wishes now to be granted an exclusive license under the Generic
Patent;

WHEREAS, Novartis agrees to grant MIP an exclusive license provided MIP pays
additional considerations to Krenning in addition to the royalties due to
Novartis under the License Agreement;

WHEREAS, the License Agreement shall be amended accordingly;

NOW, THEREFORE, in consideration of the promises, covenants and agreements
hereinafter set forth, the sufficiency of which is hereby acknowledged, the
parties to this Agreement all agree as follows:

1. DEFINITIONS:

"COMMERCIALIZATION" or "COMMERCIALIZE" shall mean activities conducted by a
Party either by itself or through a Third Party and directed to marketing,
promoting, distributing, importing,

                                                                               3

<PAGE>

exporting, offering for sale or selling a Product, which may include pre-launch
market preparation, whether undertaken by a Party alone or with a partner or a
sub-licensee. When used as a verb, "Commercialize" means to engage in
Commercialization.

"COMPOUND" shall mean the DOTA-chelated somatostatin peptide analogue known as
edotreotide.

"FIRST COMMERCIAL SALES" shall mean the first shipment of the Product to an
independent Third Party by MIP, its Affiliates, its sub-licensee, in a country
following applicable Marketing Authorization of Product in such country.

"GENERIC PATENT" shall mean the patent application GB 8828364.3, referred to as
case 100-7382, referred to as Case 118-7595 and any corresponding patent
applications or patents including any and all substitutions, extensions,
re-examination, or supplementary protection certificates, reissues, renewals,
divisions, continuations or continuations-in-part thereof, provisional patents,
patents of addition, or registrations of any kind.

"KRENNING" shall mean Dr Eric P. Krenning at the Erasmus Hospital in Rotterdam.

"KRENNING DESIGNEE" OR "DESIGNEE" shall mean an individual, corporation,
partnership, association, joint-stock company, trust, which is designated by
Krenning pursuant to lawful purposes as the beneficiary of Krenning
considerations defined under clause 3 and which is approved as such by Novartis
in writing and communicated to MIP. For the sake of clarity, Novartis will
authorize to have payments assigned to a single Designee one time for the
duration of the Krenning Agreement, except that Krenning may be entitled to ask
the payments to revert to him upon a three months prior written notice.

"KRENNING LICENSE" shall mean the agreement executed by and between Krenning and
Novartis, completing the Letter Agreement, in which Krenning and Novartis have
agreed on the ownership of the Generic Patent, on the share of the rights under
such Generic Patent and on payments of some considerations to one another.

"KRENNING MILESTONES" shall mean the milestone payments due by MIP to Krenning
as set forth in clause 2 below.

"KRENNING ROYALTIES" shall mean the royalty payments due by MIP to Krenning, as
set forth in clause 2 below.

"MAJOR EUROPEAN COUNTRY" shall mean either one of France, Germany, UK, Spain or
Italy.

"MARKETING AUTHORIZATION" shall mean the approval necessary for the
Commercialization of a Product in a specific country.

"MIP FIELD" shall mean human oncology therapeutic use.

"NET SALES" shall mean with respect to the Product the gross amount invoiced by
or on behalf of the relevant Party and its Affiliates and sublicensees for the
Product sold to Third Parties other than licensees or sublicensees in bona fide,
arms-length transactions, less customary deductions, determined in accordance
with the Party's Accounting Standards as generally and consistently applied by
that Party, to the extent included in the gross invoiced sales price of

                                                                               4

<PAGE>

any Product or otherwise directly paid or incurred by such Party, its Affiliates
or sublicensees with respect to the sale of such Product, such as:

     (i)  normal and customary trade and quantity discounts actually allowed and
          properly taken directly with respect to sales of the Product;

     (ii) amounts actually repaid or credited by reasons of defects, rejection
          recalls, returns, rebates and allowances of goods;

     (iii) chargebacks and other amounts paid on sale or dispensing of such
          Product;

     (iv) rebate amounts payable resulting from governmental mandated rebate
          programs;

     (v)  tariffs, duties, excise, sales, value- added and other taxes (other
          than taxes based on income);

     (vi) customary cash discounts for timely payment;

     (vii) delayed ship order credits;

     (viii) discounts pursuant to indigent patient programs and patient discount
          programs, including coupon discounts; and

     (x) all freight, postage and insurance included in the invoice price.

     Sales from a Party to its Affiliates shall be disregarded for purposes of
     calculating Net Sales. Any of the items set forth above that would
     otherwise be deducted from the invoice price in the calculation of Net
     Sales but which are separately charged to Third Parties shall not be
     deducted from the invoice price in the calculation of Net Sales.

     (a)  In the case of any sale or other disposal of the Product between or
          among a Party and its Affiliates or sublicensees, for resale, Net
          Sales shall be calculated as above only on the value charged or
          invoiced on the first arm's-length sale thereafter to a Third Party;

     (b)  In the case of any sale which is not invoiced or is delivered before
          invoice, Net Sales shall be calculated at the time of shipment or when
          the Product is paid for, if paid for before shipment or invoice;

"PARTY" OR "PARTIES" shall mean MIP or Novartis, or MIP and Novartis, whichever
the context admits.

"PERSON" shall mean any individual, corporation, partnership, association,
joint-stock company, trust, unincorporated organization or government or
political subdivision thereof.

"PRODUCT" shall mean the yttrium 90 radiolabeled Compound for therapeutic use
and indium 111 radiolabeled Compound for dosimetry purposes , both in a form
ready for use in human clinical trials and/or by the ultimate consumer with the
possible trademark of OctreoTher(R).

"THIRD PARTY" shall mean any Person or other entity other than MIP, Novartis or
their respective Affiliates or Sublicensees of rights conveyed under this
Agreement

2. GRANT OF AN EXCLUSIVE LICENSE

2.1 Subject to the terms and conditions of this Addendum Agreement, Novartis
hereby grants to MIP a world-wide, exclusive, royalty-bearing license under the
Generic Patent to use, make, offer to sell, sell and import the Compound and the
Product in the MIP Field, as well as to use the Indium 111 labelled Compound for
dosimetry purposes in relation to the Product therapy administration.

                                                                               5

<PAGE>

2.2 Clause 2.1 of the License Agreement is amended accordingly.

3. CONSIDERATIONS

(A) KRENNING LICENSE FEE. Upon the Effective Date, MIP shall pay to Krenning or
his Designee, the amount of USD ** ($**). Such payment will be non-refundable
and will not be subject to any claims by MIP, an Affiliate or any Third Party
for any reason, except that such payment shall be credited against royalty
payments as set forth in clause 3c) below

(B) KRENNING MILESTONE PAYMENT. In addition, following execution of the Krenning
License, MIP shall pay to Krenning or his Designee a milestone payment of USD **
($**) upon the grant of a Marketing Authorization either by the FDA, by a Major
European Country Health Authority or by the Japanese Health Authority. Such
payment will be non-refundable and will not be subject to any claims by MIP, an
Affiliate, or any Third Party for any reason.

(C) KRENNING ROYALTIES. Following the execution of the Krenning License and
further to the lump sum payments above, MIP shall pay to Krenning or his
Designee the following percentages in return for an exclusive license on the
annual world-wide Net Sales of such exclusively licensed Product:

-    ** % (** percent) of the annual Net Sales of the Product for Net Sales
     amounting less than USD ** ($**) annually.

-    ** % (** percent) of the annual Net Sales of the Product on the incremental
     sales between USD ** ($**) and USD ** ($**)

-    **% (** percent) of the annual Net sales of the Product on the incremental
     sales over USD ** ($**).

Payments to Krenning or his Designee by MIP shall be made in Euros for all Net
Sales invoiced in Euros by MIP, without currency conversion, and in US Dollars
for all other Net Sales. Such payments will be non-refundable and will not be
subject to any claims by MIP or any Third Party, for any reason, except for the
first USD ** ($**) which are offset against the first half payment of the
License Fee as set forth in 3a).

(D) ROYALTY TERM

The duration of the royalty obligation shall be determined on a country by
country basis. Royalties shall be payable quarterly from the First Commercial
Sales of the Product in such country (i) for the period such Product's use or
sale is Covered by a Valid Patent Claim in such country, or (ii) for a period of
ten (10) years from First Commercial Sales; and if both (i) and (ii) are
applicable, for the longer of either.

(E) REPORTS.

MIP shall generate a report to submit to Krenning within sixty (60) days of the
end of each calendar quarter and, after receipt of invoice from Krenning, a
sample of which is attached hereto as Schedule I, MIP shall make payment in full
to Krenning or his Designee within sixty (60) days. The report shall set forth
by country, (i) the Net Sales of Product, (ii) the number of units of Product
sold and the royalties payable hereunder, (iii) the withholding

                       *Confidential Treatment Requested*

                                                                               6

<PAGE>

taxes, if any, required by law to be deducted in respect of such sales; (iv) the
date of the First Commercial Sales of the Product in each country during the
reporting period; and (v) the exchange rates used in determining the amount of
US Dollars, for such payments that are to be made in US Dollars. With respect to
sales of the Product invoiced in Euros, the Net Sales, and royalties payable
shall be expressed in Euros. With respect to sales of the Product invoiced in a
currency other than U.S. Dollars ("USD"), the Net Sales and amounts due to
Krenning hereunder will be expressed in the US Dollars equivalent calculated on
a monthly basis in the currency of the country of sale and converted to their US
Dollar equivalent using the following method: the Net Sales in each country in
the Territory at each quarterly period in US Dollars shall be calculated by
translating the cumulative Net Sales in local currency in each country in the
Territory into those in US Dollars using the exchange rate mechanism in
accordance with General Accounting Practice (GAP) as generally and consistently
applied by U.S. Commercial Pharmaceutical Companies, normally used and approved
by MIP accountants for such currency calculations.

(F) AUDITS.

Upon the written request of Krenning, and not more than once in each calendar
year, MIP shall permit an independent certified public accounting firm of
nationally recognized standing, selected by Krenning and reasonably acceptable
to MIP, at Krenning's expense, to have access during normal business hours to
such records of MIP as may be reasonably necessary to verify the accuracy of the
royalty reports hereunder for any years ending not more than twenty-four (24)
months prior to the date of such request. The accounting firm shall disclose to
Krenning only whether the records are correct or not and the specific details
concerning any discrepancies. All other confidential information of the
accounting firm, including working papers, shall be shared exclusively with the
legal counsel representing the requesting party, and its subcontractors, for the
purpose of analysis and verification, on a confidential basis, such that
information provided by the accounting firm shall not be disclosed to the
requesting party.

     If such accounting firm concludes that additional royalties were owed
during such period, MIP shall pay the additional royalties within thirty (30)
days of the date of Krenning delivery to MIP such accounting firm's written
report so concluding. The fees charged by such accounting firm shall be paid by
Krenning, provided however, that if the audit discloses that the royalties
payable by MIP for the audited period are more than one hundred and five ten
percent (105%) of the royalties actually paid for such period, then MIP shall
pay the reasonable and direct fees and expenses charged by such accounting firm.
Any overpayment determined pursuant to this provision shall be credited to the
next payment due hereunder from MIP. If no further payments by MIP will be due
hereunder then a refund of any such overpayment will be made within thirty (30)
days of the delivery of a detailed written accountants' report to the Parties
hereto.

(G) UNDERPAYMENTS.

If at any time during the term of the Agreement and thereafter, it is determined
that MIP underreported sales to Krenning, then any royalty payments related to
such under reporting of sales shall be reported and paid to Krenning or his
Designee within sixty (60) days of MIP's first knowledge of such underpayment
with Interest.

(G) INTEREST.

Payments due by MIP under the Agreement, when overdue, shall bear interest at a
rate per annum equal to LIBOR (London Interbank Offered Rate) plus one percent
(1%) at the time

                                                                               7

<PAGE>

such payment is due, and for the time period until payment is received by
Krenning or his Designee.

(H) CONFIDENTIAL FINANCIAL INFORMATION.

Krenning shall treat all financial information subject to review under this
Article 3 as confidential and shall cause its accounting firm to retain all such
financial information in confidence.

(I) PAYMENT METHOD.

Royalty, License Fee and Milestone Payment and Interest payments by MIP under
the Agreement shall be paid in US Dollars and/or in Euros, by bank wire transfer
or bank check in immediately available funds to such account as Krenning shall
designate before such payment is due.

(J) EXCHANGE CONTROL. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country where each
Product is sold, payment shall be made through such lawful means or methods as
MIP shall reasonably shall determine after consultation with Krenning.

(K) ROYALTY ACCRUAL. There shall be no obligation to pay Krenning royalties on a
reasonable amount of samples lawfully used in the Territory and on Product used
(and not sold) during pre-clinical or clinical testing, or for physician
preference testing, teaching or experimental purposes, or for any other similar
pre-commercial uses of Product.

(L) DESIGNEE. Novartis MIP payment to Krenning Designee shall relieve MIP of any
identical payment to Krenning. MIP shall not be liable for any additional tax or
costs that such Third Party beneficiary payment may cause.

4. SUPPLY OF THE PRODUCT

Commercial Supply to Erasmus Hospital. In the event that the Product is
commercialised in Europe, including in the Netherlands, MIP shall discuss in
good faith with Krenning and the Erasmus Hospital the supply procedure of the
Product to the Hospital under which the Hospital shall be granted a reasonable
quantity of the Product for its commercialisation requirements for a price which
shall in no event be greater than the price agreed with other hospitals in
Europe with similar size and stature.

5. PATENT MAINTENANCE AND DEFENSE

In the event that Novartis has lost interests in the Generic Patent and has
offered it to MIP, MIP undertakes the following:

     a) MIP will keep Krenning informed before taking any major decision
     relating to the maintenance of the Generic Patent, and shall provide
     written notification of such change no less than ninety (90) days prior to
     any change relating to the maintenance of the Patents in a country.

                                                                               8

<PAGE>

     b) in the event that MIP decides to abandon the Generic Patent in one or
     several countries, it shall provide written notice to Krenning thereof no
     less than ninety (90) days prior to the final date for filing a response or
     submitting a payment to the relevant governmental office regarding such
     Generic Patent after which the Generic Patent would become abandoned. After
     receiving such notice, Krenning may, but is not obligated to, elect to
     continue preparation, filing and prosecution or maintenance of the
     discontinued Generic Patent at his sole expense. Ownership of any such
     discontinued Generic Patent shall at the request of Krenning be fully
     assigned by MIP to Krenning and MIP shall promptly prepare and execute such
     documents and perform such acts as may be reasonably necessary for
     assigning such sole ownership to Krenning at MIP's sole expense and at no
     cost to Krenning. Krenning shall be responsible for the filing of any such
     documents, and the expenses related to such filings.

     c) MIP shall have the first right, but not the obligation to take,
     institute and prosecute legal proceedings in case of Generic Patent rights
     infringement or to control the defense of any declaratory judgment action
     relating to the Generic Patent.

6. CONFIDENTIALITY

Except for the right to disclose the terms of this Addendum Agreement to
Krenning, the terms and conditions of this Addendum Agreement shall be
confidential and subject to the conditions as set forth in Article 9 of the
License Agreement.

7. ENTIRE AGREEMENT

Except as set forth in Section 2,3 and 5, this Addendum Agreement and its
Schedule I shall not replace, amend, supersede or be in lieu of any provisions
set forth in the License Agreement.

8. ADDITIONAL AGREEMENT

Novartis agrees that MIP shall be entitled to enter into a separate agreement
with Krenning setting forth further terms and conditions of their collaboration.

                                                                               9

<PAGE>

                                   Schedule I

                                Sample of Invoice

                                                                         INVOICE

SENDER'S LOGO
Street                                                         INVOICE DATE:
Town, Country                                                  XXXXX, 200X
Phone and Fax Nr.

                                                               INVOICE NO.: XXXX

BILL TO:                                 FOR:

Molecular Insight Pharmaceuticals Inc.   Product X Royalties 1st Quarter 200X

160 Second Street,                       (or Milestone for event Y)

Cambridge, MA 02142 USA

<TABLE>
<CAPTION>
             DESCRIPTION                  AMOUNT (USD)
             -----------                 -------------
<S>                                      <C>
Product X royalties January - March      US$000,000.00
200X calculated based on Novartis
provided sales report (see attached
worksheet)

(Or milestone payment for event Y,
according to paragraph XY of agreement
ZZZZ dated ____________)

Novartis/MIP Contract Code

Please specify the event for which the
invoice is due, and add any copies of
invoices from third parties in case
reimbursement for third party work is
agreed to

PLEASE REMIT BY WIRE TRANSFER WITHIN 60 DAYS TO:

   Receiving Bank - __________

   Swift Code     - __________

   IBAN Number    - __________

   Credit Account - __________

   Beneficiary    - __________

      TOTAL                                 000,000.00
</TABLE>

If you have any questions concerning this invoice, contact __________ or e-mail
to __________

                                                                              10

<PAGE>

VAT -Reg. No. Xxxxxxxxxx (only if applicable)

                                         BEST REGARDS,

                                         ---------------------------------------

                                                                              11<PAGE>
                                                                   EXHIBIT 10.30

                          TECHNOLOGY TRANSFER AGREEMENT

     THIS TECHNOLOGY TRANSFER AGREEMENT (the "Agreement") is entered into
effective as of the 20th day of December 2006 (the "Effective Date"), by and
between Mallinckrodt Inc., a Delaware corporation, with a place of business at
675 McDonnell Boulevard, Hazelwood, Missouri 63042 ("MALLINCKRODT"), and
Molecular Insight Pharmaceuticals, Inc., a Delaware corporation, with an office
at 160 Second Street, Cambridge, Massachusetts 02142 ("MIP").

     WITNESSETH THAT:

     WHEREAS, MIP plans to enter a license agreement with Novartis Pharma AG
("Novartis") for the right to make, use, sell, offer for sale and import the
Product (as defined in Section 1 below); and

     WHEREAS, MALLINCKRODT owns or is the licensee of certain Patent Rights (as
defined in Section 1 below), claiming a method of stabilization of
radiopharmaceuticals; and

     WHEREAS, MALLINCKRODT has technology and capability to manufacture Vials
(as defined in Section 1 below) and the Product; and

     WHEREAS, MIP desires to obtain a license to the Patent Rights and
Technology (as defined in Section 1 below), and to receive a transfer of the
Technology for the Vials and the Product as detailed in EXHIBIT B; and

     WHEREAS, MALLINCKRODT is willing to grant the license and to provide the
transfer of the Technology upon the terms and conditions set forth in this
Agreement;

     NOW THEREFORE, in consideration of the premises and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, MALLINCKRODT and MIP agree as follows:

1. DEFINITIONS. Wherever used in this Agreement, the following capitalized terms
shall have the meanings set forth below:

     1.1 "AFFILIATE" means any entity that directly or indirectly controls or is
controlled by or is under common control with a Party to this Agreement. For
purposes of this definition, "control" or "controlled" means ownership directly
or through one or more Affiliates, of fifty percent (50%) or more of the shares
of stock entitled to vote for the election of directors, in the case of a
corporation, or fifty percent (50%) or more of the equity interest in the case
of any

<PAGE>

other type of legal entity, status as a general partner in any partnership, or
any other arrangement whereby a Party controls or has the right to control the
board of directors or equivalent governing body of a corporation or other
entity, or the ability to cause the direction of the management or policies of a
corporation or other entity.

     1.2 "AGREEMENT" shall mean this Technology Transfer Agreement together with
all exhibits, schedules and appendices hereto, all as the same may be amended,
modified or supplemented from time-to-time in accordance with the terms of this
Agreement.

     1.3 "CHANGE OF CONTROL" shall mean any of the following events: (i) any
Third Party (or group of Third Parties acting in concert) becomes the beneficial
owner, directly or indirectly, of fifty percent (50%) or more of the voting
power of the stock then outstanding of MIP; (ii) MIP consolidates with or merges
into another corporation or entity, or any corporation or entity consolidates
with or merges into MIP, in either event pursuant to a transaction in which
fifty percent (50%) or more of the total voting power of the stock outstanding
of the surviving entity normally entitled to vote is not held by Persons holding
more than fifty percent (50%) of the outstanding shares of MIP prior to such
consolidation or merger; (iii) any Third Party (or group of Third Parties acting
in concert) obtains the power to direct or cause the direction of the management
and policies of MIP by any lawful means whatsoever; or (iv) MIP conveys,
transfers or leases all or substantially all of its assets.

     1.4 "COMPOUND" means DOTA-Tyr(3)-Octreotide.

     1.5 "EFFECTIVE DATE" shall mean the later to occur of (i) the date upon
which MALLINCKRODT receives written notice from MIP that MIP has executed the
agreement with Novartis as referenced in Section 8 hereof and (ii) the date upon
which the Termination Letter shall have been executed by and between
MALLINCKRODT and Novartis.

     1.6 "FDA" means the United States Food and Drug Administration and any
successor agency thereto.

     1.7 "GOOD MANUFACTURING PRACTICES" or "GMP" means the then current Good
Manufacturing Practices as such term is defined from time to time by the FDA or
other relevant governmental authority having jurisdiction over the development,
manufacture or sale of the Product in any other country pursuant to its
regulations, guidelines or otherwise.

     1.8 "MALLINCKRODT CONFIDENTIAL INFORMATION" means all Technology, data and
other information that is disclosed by MALLINCKRODT to MIP during the course of
providing the technology transfer services under this Agreement to the extent
that such

                                        2

<PAGE>

information as of the date of disclosure to MIP is not (i) known to MIP other
than by virtue of a prior confidential disclosure to MIP by MALLINCKRODT; or
(ii) disclosed in published literature, or otherwise generally known to the
public through no fault or omission of MIP; or (iii) obtained from a Third Party
free from any obligation of confidentiality to MALLINCKRODT.

     1.9 "MIP CONFIDENTIAL INFORMATION" means all information about MIP's
technical requirements with respect to the Product which is disclosed by MIP to
MALLINCKRODT and designated "Confidential" in writing by MIP at the time of
disclosure to MALLINCKRODT to the extent that such information is not (i) as of
the date of disclosure to MALLINCKRODT demonstrably known to MALLINCKRODT other
than by virtue of a prior confidential disclosure to MALLINCKRODT by MIP; or
(ii) as of the date of disclosure or thereafter is disclosed in published
literature, or otherwise generally known to the public through no fault or
omission of MALLINCKRODT; or (iii) obtained from a Third Party free from any
obligation of confidentiality to MIP; or (iv) MALLINCKRODT can demonstrate by
competent evidence was developed by MALLINCKRODT or its Affiliates without
access to or the benefit of MIP Confidential Information. MIP will not disclose
any information to MALLINCKRODT regarding MIP's marketing plans or
commercialization with respect to the Product or to the Indium 111 labelled
Compound for dosimetry planning for OctreoTher therapy delivery and to the
extent disclosed, such information shall not be deemed MIP Confidential
Information for purposes of this Agreement and MALLINCKRODT shall not be under
any limitations with respect thereto.

     1.10 "MIP FIELD" means human oncology therapeutic use.

     1.11 "OCTREOTHER(R)" means the trademark selected and owned by Novartis for
the Product.

     1.12 "PARTY" OR "PARTIES" shall mean MIP or MALLINCKRODT, or MIP and
MALLINCKRODT, whichever the context admits.

     1.13 "PATENT RIGHTS" means the patents and patent applications listed in
EXHIBIT A, and patents issuing on them, including any division, continuation,
continuation-in-part, renewal, extension, re-examination, reissue or foreign
counterpart thereof.

     1.14 "PERSON" shall mean any individual, corporation, partnership,
association, joint stock company, trust, unincorporated organization or
government or political subdivision thereof.

                                       3

<PAGE>

     1.15 "PRODUCT" means the OctreoTher Hot Liquid which is the radiolabeled
peptide (90)Y DOTA-Tyr(3)-Octreotide (Yttrium ((90)Y) SMT 487) in a solution
prepared from the reconstituted Vials.

     1.16 "REGULATORY AUTHORITY" shall mean the FDA or any foreign counterpart
or additional governmental or regulatory agencies in the Territory with
responsibility for marketing approval or authorization of the Product.

     1.17 "TECHNOLOGY" means and is limited to the specific materials, technical
information, know-how, expertise, trade secrets and the associated documentation
in MALLINCKRODT's possession and required for:

          -    the manufacturing and quality control of the Vials; and

          -    the manufacturing and quality control of the Product.

MIP acknowledges that the term "Technology" does not include any know-how,
expertise or trade secret information, if any, that MALLINCKRODT may have
regarding the labelling of the Compound with Indium-111. Without limiting the
generality of the preceding sentence, MALLINCKRODT shall be under no obligation
whatsoever to provide a Technology transfer to MIP with respect to the labelling
of the Compound with Indium-111.

     1.18 "TERRITORY" shall mean all of the countries and territories of the
world.

     1.19 "TERMINATION LETTER" shall mean an agreement to be entered into by
MALLINCKRODT and Novartis providing for the termination of (i) that certain
agreement, dated December 1, 1992, between Sandoz Pharma Ltd. (now Novartis) and
Mallinckrodt Medical Inc. (now MALLINCKRODT) relating to the development,
manufacture and marketing of molecules for radiodiagnostic and radiotherapeutic
purposes and (ii) that certain agreement, dated October 1996, under which
MALLINCKRODT and Novartis agreed to collaborate in the development, manufacture
and marketing of the Product.

     1.20 "THIRD PARTY" shall mean any Person or other entity other than MIP,
MALLINCKRODT or their respective Affiliates.

     1.21 "VIAL" means the OctreoTher SMT 487 Reaction Vial which is a vial
containing lyophilized material comprised of DOTA-Tyr(3)- Octreotide, gentisic
acid, inositol, ascorbic acid, and sodium hydroxide that is reconstituted to
make the Product.

2. GRANT OF LICENSE, TERM, RIGHTS AND OBLIGATIONS.

     2.1 LICENSE GRANTED TO MIP UNDER THE PATENT RIGHTS AND TECHNOLOGY. Subject
to

                                       4

<PAGE>

the terms, conditions and limitations of this Agreement, MALLINCKRODT hereby
grants to MIP a non-exclusive, worldwide license under all of MALLINCKRODT's
right, title and interest in the Patent Rights and Technology, to manufacture,
use, sell, offer for sale and import the Product in the MIP Field, as well as to
use the Indium 111 labelled Compound for dosimetry purposes in relation to the
Product therapy administration; provided that MIP can only exercise the
foregoing rights with respect to an Indium 111 labelled Compound to the extent
the FDA or other Regulatory Authority expressly requires the development and use
thereof for dosimetry purposes as a condition to its approval of the Product for
marketing and sale, and provided further that MIP may under no circumstances
market and sell an Indium-111 labelled Compound separately as a diagnostic
imaging agent (i.e., the Indium-labelled Compound can only be marketed and sold
for dosimetry purposes in relation to Product therapy administration). Except as
specifically provided in this Agreement, no licenses are granted by MALLINCKRODT
and MALLINCKRODT retains all other rights under the Patent Rights and the
Technology.

     MIP shall have the right to grant sublicenses with respect to the license
rights provided for in this Section 2.1 solely on the following terms and
conditions.

          (a) Without MALLINCKRODT'S prior written consent, which MALLINCKRODT
may grant or withhold in its sole and absolute discretion, and notwithstanding
anything to the contrary forth in this Agreement, MIP cannot sublicense any
rights to a direct competitor of MALLINCKRODT, as listed in EXHIBIT G.

          (b) In the event MIP intends to grant rights of any nature whatsoever
with respect to the commercialization, including but not limited to the
marketing, promoting, distributing, importing or selling, of the Product to any
Third Party(ies), MIP must first offer any such commercialization rights, in
writing, to MALLINCKRODT. Upon receipt of such offer, MALLINCKRODT shall have
sixty (60) days to inform MIP whether it desires to enter into good faith
negotiations with MIP for a definitive agreement with respect to such rights.
Mallinckrodt's rights under this subsection are subject to MIP's obligation to
first provide Novartis with "rights of first discussions", as set forth in
Section 6.5 of the agreement to be entered into between MIP and Novartis
relating to the Product, as referenced in Section 8 of this Agreement.

          (c) MIP shall in all events remain directly responsible to
MALLINCKRODT for the performance by any sublicensee of any and all obligations
and/or responsibilities assumed by such sublicensee under this Agreement.

                                       5

<PAGE>

          (d) The terms and conditions of any Third Party sublicense shall be
consistent in all respects with the terms of this Agreement.

          (e) MIP shall cause each sublicensee to execute any and all additional
documents reasonably requested by MALLINCKRODT to reflect the conditions set
forth above.

     2.2 TERM OF LICENSE. The term of the license set forth in Section 2.1 shall
commence on the Effective Date and, unless sooner terminated pursuant to Article
9 of this Agreement, shall terminate on a country-by-country basis on the date
when MIP discontinues manufacture and/or sale of the Product, as the case may
be, in such country.

     2.3 TRANSFER OF THE TECHNOLOGY.

          (a) During the period commencing no later than thirty (30) days after
the Effective Date and terminating not later than one-hundred eighty (180) days
thereafter, MALLINCKRODT shall make available research and development and
production personnel to physically transfer the Technology to MIP personnel.
Such MALLINCKRODT personnel shall be knowledgeable about the Technology, shall
be reasonably capable of transferring the Technology to MIP, and shall use
commercially reasonable efforts to transfer the Technology to MIP personnel. MIP
must at all times during the one-hundred eighty (180) period referenced in the
preceding sentence provide knowledgeable and capable personnel to be the
recipients of the transfer of the Technology. Exhibit B is an all-inclusive list
of the specific services to be provided by MALLINCKRODT personnel hereunder.
MALLINCKRODT shall transfer the Technology to MIP on an "AS IS" basis.

          (b) MALLINCKRODT's obligation to provide transfer of the Technology is
in all events limited to ninety (90) work days (i.e., one MALLINCKRODT employee
working ninety (90) days at eight (8) hours per day) or completion by
MALLINCKRODT of the specific services identified in Exhibit B, whichever comes
first.

          (c) For purposes of calculating the amount of time devoted by
MALLINCKRODT personnel to the transfer of Technology required under this
Agreement, each response by MALLINCKRODT to a request by MIP or its Affiliates
for assistance, whether in the form of a written communication, oral request, or
otherwise, shall be accounted for as an expenditure of time equal to the greater
of (i) four (4) hours or (ii) the actual time spent by MALLINCKRODT responding
to the request for assistance. For example, if an employee of MIP requests, by
telephone call, assistance with Technology transfer and a MALLINCKRODT employee
devotes two (2) hours responding to the request, MALLINCKRODT shall, for

                                       6

<PAGE>

purposes of this Agreement, be considered to have provided four (4) hours of
Technology transfer services.

          (d) In the event the MALLINCKRODT personnel referenced above are
required to travel away from their regular place of employment, MIP will
reimburse MALLINCKRODT for all reasonable travel and living expenses incurred by
such personnel upon submission by MALLINCKRODT of an itemized account of
expenses for which it seeks reimbursement. Travel time will be considered
working time of MALLINCKRODT employees for purposes of determining
MALLINCKRODT's compliance with its obligations under this Section.

     2.4 ADDITIONAL TRANSFER OF THE TECHNOLOGY. If, during the first twelve (12)
months this Agreement is in effect, MIP determines that it requires additional
Technology transfer from MALLINCKRODT, MIP shall provide to MALLINCKRODT a list
of its specific additional requirements for MALLINCKRODT's consideration. If the
request is acceptable to MALLINCKRODT in its reasonable discretion, MALLINCKRODT
shall provide up to an additional ninety (90) work days in thirty (30) work day
increments of Technology transfer during a similar period and in the manner set
forth in Section 2.3. MIP shall make the payment described in Section 3(d) prior
to the commencement of such additional Technology transfer.

     2.5 CERTIFICATION BY MALLINCKRODT. Upon completion by MALLINCKRODT of its
obligation(s) to transfer the Technology under Sections 2.3 and/or 2.4 of this
Agreement, MALLINCKRODT shall provide a written certification of completion to
MIP in the form attached to this Agreement as EXHIBIT C. Absent manifest error
demonstrated by MIP, and subject to MIP's rights to additional technical
support, if applicable, as set forth in Section 2.4, such certification shall
for all purposes be deemed conclusive and final evidence of MALLINCKRODT's full
and complete performance of its Technology transfer obligations to MIP.

     2.6 LIAISON. Each of MIP and MALLINCKRODT shall within ten (10) days of the
execution of this Agreement identify a primary contact person to act as liaison
for the purposes of implementing this Agreement.

3. PAYMENTS. MIP shall make the following payments to MALLINCKRODT by wire
transfer in United States Dollars to an account designated by MALLINCKRODT:

          (a) $** concurrent with the execution of this Agreement;

                       *Confidential Treatment Requested*

                                       7

<PAGE>

          (b) $** upon commencement by MALLINCKRODT of the Technology
     transfer as detailed in Exhibit B;

          (c) $** upon completion of the Technology transfer as detailed
     in Exhibit B; and

          (d) $** for each thirty (30) day increment of the additional
     Technology Transfer pursuant to Section 2.4, payable upon commencement by
     MALLINCKRODT of each such increment.

4. SALE OF OCTREOTHER VIALS.

     4.1 MALLINCKRODT hereby sells and MIP buys the 1,800 Vials in
MALLINCKRODT's possession. The purchase price is U.S. $**, ** percent
(**%) of which is payable by wire transfer concurrent with the execution of this
Agreement and the balance of which is payable upon confirmation of delivery to
MIP.

     4.2 Terms of delivery for the Vials shall be FOB, MALLINCKRODT's facility
in Petten, The Netherlands. MALLINCKRODT shall cause the Vials to be shipped
within thirty (30) days after the later of execution of this Agreement and
receipt by MALLINCKRODT of the ** percent (**%) installment, as described in
Section 4.1 above, unless directed otherwise by MIP and agreed upon by
MALLINCKRODT in its discretion.

     4.3 MALLINCKRODT warrants that the Vials have been manufactured in
accordance with GMP standards and meet the specifications in Section 5.2.1 of
the Yttrium ((90)Y) SMT 487 IND Information Manufacturing Description attached
to this Agreement as EXHIBIT D. MALLINCKRODT MAKES NO OTHER WARRANTY, EXPRESS OR
IMPLIED, WITH RESPECT TO THE VIALS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, EXCEPT AS SET FORTH IN SECTION 6.

5. MIP RESPONSIBILITIES. Upon the Effective Date, MIP will be solely
responsible, at its own cost, for all regulatory filings, development and
clinical and commercial manufacture of all Product. MALLINCKRODT will have no
responsibilities or obligation of any kind with respect to these activities.

6. REPRESENTATION AND WARRANTY.

     6.1 MALLINCKRODT represents and warrants to MIP that, upon execution of the

                       *Confidential Treatment Requested*

                                       8

<PAGE>

Termination Agreement by Novartis, it will have the right to grant the license
granted pursuant to Section 2.1 of this Agreement, and that the license so
granted will not conflict with or violate the terms of any agreement between
MALLINCKRODT and any Third Party.

7. TREATMENT OF CONFIDENTIAL INFORMATION.

     7.1 CONFIDENTIALITY.

          7.1.1 Subject to MIP's rights with respect to the licenses as
specifically provided for in Section 2.1 of this Agreement, MIP and MALLINCKRODT
each agree that during the term of this Agreement and for five (5) years
thereafter, it will keep confidential, and will cause its Affiliates and
sublicensees to keep confidential, all MALLINCKRODT Confidential Information or
MIP Confidential Information, as the case may be, which is disclosed to it or to
any of its Affiliates and sublicensees pursuant to this Agreement. Neither MIP,
its Affiliates or sublicensees, nor MALLINCKRODT shall use Confidential
Information of the other Party except as expressly permitted under this
Agreement.

          7.1.2 Each Party agrees that it will disclose the other Party's
Confidential Information to its officers, employees, agents or Affiliates only
if and to the extent necessary to carry out its responsibilities under this
Agreement and shall limit disclosures to the extent possible consistent with
such responsibilities. MALLINCKRODT agrees not to disclose MIP Confidential
Information to any Third Parties under any circumstance without written
permission from MIP. MALLINCKRODT shall take such action, and shall cause its
Affiliates to take such action, to preserve the confidentiality of MIP
Confidential Information as it would customarily take to preserve the
confidentiality of its own Confidential Information. Upon termination of this
Agreement, MALLINCKRODT will, upon MIP's written request, either return or, in
MALLINCKRODT's discretion, destroy all the MIP Confidential Information
disclosed to it by MIP pursuant to this Agreement, including all copies and
extracts of documents, within sixty (60) days of the request except for one (1)
copy which may be kept for the purpose of complying with continuing obligations
under this Agreement.

          7.1.3 The Parties represent that all employees who shall have access
to Confidential Information are or will be bound by agreements to maintain such
information in confidence.

          7.1.4 Notwithstanding any of the foregoing provisions, MIP
specifically acknowledges and agrees that all confidential and proprietary
information provided by

                                       9

<PAGE>

MALLINCKRODT to MIP in connection with the negotiation, execution and
performance of this Agreement shall also be and remain subject to the terms of
that certain Confidentiality Agreement, dated November 14, 2005, between the
Parties (the "MALLINCKRODT Confidentiality Agreement.") In the event of any
inconsistencies between the terms of this Agreement and the MALLINCKRODT
Confidentiality Agreement, the terms of the MALLINCKRODT Confidentiality
Agreement shall govern, except that MIP shall, without regard to the terms of
the MALLINCKRODT Confidentiality Agreement, be authorized to communicate
MALLINCKRODT Confidential Information to a permitted sublicensee hereunder (as
provided for in Section 2.1) to the extent required for the performance by such
permitted sublicensee of the obligations that are subject to the sublicense.

     7.2 PUBLICITY. Except as required by law, and except for a mutually
approved press release to be issued upon the signing of this Agreement, neither
Party may disclose the terms of this Agreement without the written consent of
the other Party; provided, however, that MIP may disclose the terms, or provide
copies, of this Agreement as necessary in the normal course of business to
bankers, investors and others in order to obtain financing.

     7.3 DISCLOSURE REQUIRED BY LAW. If MALLINCKRODT is requested to disclose
MIP Confidential Information in connection with a legal or administrative
proceeding or is otherwise required by law to disclose the Confidential
Information, it will give MIP prompt notice of such request. MIP may seek an
appropriate protective order or other remedy or waive compliance with the
provisions of this Agreement. If MIP seeks a protective order or other remedy,
MALLINCKRODT will cooperate at MIP's sole cost and expense. If MIP fails to
obtain a protective order or waive compliance with the relevant provisions of
this Agreement, MALLINCKRODT will disclose only that portion of MIP Confidential
Information which its legal counsel determines it is required to disclose.

8. NO OTHER AGREEMENTS. Except for the MALLINCKRODT Confidentiality Agreement,
this Agreement is the sole agreement between the Parties with respect to the
subject matter hereof and supersedes all other agreements and understandings
between the Parties with respect to same; provided, however, the execution of
the proposed agreement between MIP and Novartis with respect to the Product
prior to or on even date with this Agreement, together with the execution by
MALLINCKRODT and Novartis of the Termination Agreement, are condition precedents
to the force and effectiveness of this Agreement. If such agreement is not
executed in

                                       10

<PAGE>

the time described, this Agreement will lapse and the Parties will have no
obligation of any kind to each other; provided that such lapse will have no
effect on the continuing enforceability of the MALLINCKRODT Confidentiality
Agreement in accordance with its terms.

9. TERMINATION AND DISENGAGEMENT.

     9.1 MATERIAL BREACH. If either MIP or MALLINCKRODT shall breach any
material obligation contained in this Agreement and, in the case of a breach
capable of remedy, such breach shall not be cured within sixty (60) days (ten
(10) days with respect to a payment default) after written notice to the
breaching Party, the Party not in breach may terminate this Agreement by notice
without prejudice to the accrued rights of either Party.

     9.2 TERMINATION FOR INSOLVENCY. Either Party may terminate this Agreement
immediately upon delivery of written notice to the other Party: (i) upon the
institution by or against the other Party of insolvency, receivership or
bankruptcy proceedings or any other proceedings for the settlement of the other
Party's debts; provided, however, with respect to involuntary proceedings, that
such proceedings are not dismissed within one hundred and twenty (120) days;
(ii) upon the other Party's making an assignment for the benefit of creditors;
or (iii) upon the other Party's dissolution or ceasing to do business.

     9.3 CHANGE OF CONTROL. MALLINCKRODT may terminate this Agreement
immediately in the event there is a Change in Control, provided such Change in
Control results in MIP being owned by a direct competitor of MALLINCKRODT, as
listed on Exhibit G hereto.

     9.4 EFFECT OF TERMINATION.

          (a) The expiration of termination of this Agreement for any reason
shall not relieve the Parties from any obligations that accrued prior to such
expiration or termination, including without limitation MALLINCKRODT's right to
receive all payments accrued hereunder as of the effective date of expiration or
termination. In addition, except where explicitly elsewhere provided herein,
termination of this Agreement for any reason, or expiration of this Agreement,
will not affect any rights or obligations which, from the context thereof, are
intended to survive termination or expiration of this Agreement.

          (b) In the event this Agreement is rightfully terminated by
MALLINCKRODT pursuant to Sections 9.1, 9.2 or 9.3, (i) all of MIP's rights to
the Patent Rights and the Technology shall immediately revert to MALLINCKRODT,
including but not limited to all rights under the license conveyed pursuant to
Section 2.1 of this Agreement, and

                                       11

<PAGE>

(ii) MALLINCKRODT shall be entitled to immediately cease all Technology transfer
activities otherwise remaining to be performed under this Agreement.

          (c) In the event this Agreement is rightfully terminated by MIP
pursuant to Sections 9.1 or 9.2, MIP's license rights in and to the Patent
Rights and the Technology shall nevertheless continue in full force and effect
in accordance with the terms of this Agreement.

10. INDEMNIFICATION. MIP hereby agrees to indemnify, defend and hold harmless
MALLINCKRODT (and all officers, directors, employees, agents and other
Affiliates of MALLINCKRODT) for any and all claims, liabilities, damages,
losses, costs or expenses (including but not limited to reasonable attorneys'
fees) arising from or in connection with (i) any breach by MIP of a material
obligation under this Agreement, (ii) clinical trials pursued by MIP, its
Affiliates or sublicensees with respect to the Product or the Compound or (iii)
the development, manufacture, marketing and/or sale of the Product by MIP, its
Affiliates or sublicensees. MIP shall choose legal counsel, shall control the
defense of such claim or action and shall have the right to settle same on such
terms and conditions it deems advisable.

11. LIMITATION OF DAMAGES. Neither Party nor their respective Affiliates shall
have any liability for any special, incidental or consequential damages,
including but not limited to loss of opportunity, revenue or profit, in
connection with or arising out of this Agreement, even if it shall have been
advised of the possibility of such damages.

12. NOTICES. All notices shall be in writing mailed via certified mail, return
receipt requested, courier, or facsimile or other e-mail transmission addressed
as follows, or to such other address as may be designated from time to time:

     IF TO MIP: Molecular Insight Pharmaceuticals, Inc.
                160 Second Street
                Cambridge, Massachusetts 02142
                Attn: Vice President, Commercial and Business Development

     WITH COPY TO: Joshua A. Kalkstein, Esq.
                   Robinson & Cole LLP

                                       12

<PAGE>

                   One Boston Place
                   Boston, MA 02108

     IF TO MALLINCKRODT: Mallinckrodt Inc.
                         675 McDonnell Blvd.
                         St. Louis, MO 63134
                         Attn: President, Imaging Division

     WITH COPY TO: Mallinckrodt Inc.
                   675 McDonnell Blvd.
                   St. Louis, MO 63134
                   Attn: Vice President Legal, Imaging Division

Notices shall be deemed given as of the date received.

13. GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware without giving effect to the
principles of conflicts of laws thereof or any other law that would apply the
law of another jurisdiction.

14. MISCELLANEOUS.

     14.1 BINDING EFFECT. This Agreement shall be binding upon and inure to the
benefit of the Parties and their respective legal representatives, heirs,
successors and permitted assigns.

     14.2 HEADINGS. Paragraph headings are inserted for convenience of reference
only and do not form a part of this Agreement.

     14.3 COUNTERPARTS. This Agreement may be executed simultaneously in two or
more counterparts, each of which shall be deemed an original. Signatures may be
transmitted via facsimile, thereby constituting the valid signature and delivery
of this Agreement.

     14.4 AMENDMENT; WAIVER; ETC. This Agreement may be amended, modified,
superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each Party or, in the case of waiver, by the Party or
Parties waiving compliance. The delay or failure of any Party at any time or
times to require performance of any provisions shall in no manner affect the
rights at a later time to enforce the same. No waiver by any Party

                                       13

<PAGE>

of any condition or of the breach of any term contained in this Agreement,
whether by conduct, or otherwise, in any one or more instances, shall be deemed
to be, or considered as, a further or continuing waiver of any such condition or
of the breach of such term or any other term of this Agreement.

     14.5 NO THIRD PARTY BENEFICIARIES. No Third Party including any employee of
any Party to this Agreement, shall have or acquire any rights by reason of this
Agreement. Nothing contained in this Agreement shall be deemed to constitute the
Parties as partners with each other or any Third Party.

     14.6 ASSIGNMENT AND SUCCESSORS. MALLINCKRODT may not assign its Technology
transfer obligations under this Agreement to any Third Party without MIP's
consent, which will not be unreasonably withheld, other than to an Affiliate,
any purchaser of all or substantially all of MALLINCKRODT's assets, or to any
successor corporation resulting from any merger or consolidation of MALLINCKRODT
with or into such corporation. MIP may not transfer or assign any of its rights
or obligations under this Agreement without the express, prior written consent
of MALLINCKRODT, which MALLINCKRODT may withhold in its sole discretion in the
event the proposed assignee is a MALLINCKRODT competitor as listed on Exhibit G
hereto. With respect to any other assignee (i.e., an assignee not listed on
Exhibit G), MALLINCKRODT will not unreasonably withhold its consent to the
proposed transfer or assignment. Any attempted assignment or transfer in
contravention of this Section shall, at the option of the non-assigning Party,
be null and void and of no effect. No assignment shall release either Party from
responsibility for the performance of any accrued obligation of such Party
hereunder.

     14.7 FORCE MAJEURE. Neither MIP nor MALLINCKRODT shall be liable for
failure of or delay in performing obligations (other than payment obligations)
set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes
reasonably beyond the control of MIP or MALLINCKRODT.

     14.8 SEVERABILITY. If any provision of this Agreement is or becomes invalid
or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the
Agreement shall not be affected so long as the essential benefits of this
Agreement remains enforceable and obtainable.

                                       14

<PAGE>

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representatives as of the date first above written.

MOLECULAR INSIGHT                       MALLINCKRODT INC.
PHARMACEUTICALS, INC.

By: /s/ David Barlow                    By: /s/ Steve Hanley
    ---------------------------------       ------------------------------------
    David Barlow                            Steve Hanley

Title:  -----------------------------   Title: ---------------------------------
Chairman and CEO, Molecular             President, Imaging Division
Insight Pharmaceuticals, Inc.

Date: December 19, 2006                 Date: 12/20/06
      -------------------------------        -----------------------------------

                                       15

<PAGE>

                                    EXHIBIT A

                                  US 5,384,113

                                  EP 600 992B1

                                        AT 196428T
                                        BE 600 992
                                        CH 600 992
                                        DE 692231469T
                                        DK 600 992
                                        ES 2150916T
                                        FR 600 992
                                        GB 600 992
                                        GR 3035067T
                                        IT 600 992
                                        LU 600 992
                                        NL 600 992
                                        SE 600 992

                                   CA 2113995C

                                   JP 6510539T

                                       16
<PAGE>

                                    EXHIBIT B

     Below are the services to be provided by MALLINCKRODT for the transfer of
the Technology for the Vials and the Product to MIP. The objective of this
technology transfer is for MALLINCKRODT to provide MIP with sufficient
information and training to enable MIP to manufacture and quality control the
Vials and the Product. A timeline of activities described below appears in
EXHIBIT E.

B.1. Documentation for Vials (OctreoTher Reaction Vial) and Product (OctreoTher
Hot Liquid)

The following documents will be provided by MALLINCKRODT to MIP at least 10
business days prior to the commencement of the Transfer of Technology as
described in Section 2.3, unless otherwise agreed upon by MALLINCKRODT and MIP:

     -    R&D Reports as per Table 1, in English and in both hard copy and
          electronic pdf document format.

     -    Standard Operating Procedures as per Table 2, in the original Dutch
          and in English and in both hard copy and electronic Word document
          format.

     -    Regulatory Information Documents as per Table 3, in English and in
          both hard copy and electronic Word document format.

     -    Documents pertaining to the lyophilization process or the equipment
          necessary for the manufacturing and quality control of the Vials and
          the Product as per Table 4, in English or in Dutch and in either hard
          copy or electronic format.

     -    In addition to the items listed in Tables 1, 2, 3 and 4, MALLINCKRODT
          will provide to MIP any additional documents identified during the
          Transfer of Technology that already exist and are readily available to
          MALLINCKRODT, are required for the manufacturing and quality control
          of the Vials and the Product, and are requested by MIP.

                                       17

<PAGE>

                              TABLE 1. R&D REPORTS

<TABLE>
<CAPTION>
Number                                    Title                                       Report No.
------                                    -----                                       ----------
<S>      <C>                                                                       <C>
   1     Suitability test for a new crimp capsule for OctreoTher bottles
         (Helvoet code 1C325-3-C39)                                                    01ewe03r

   2     IN-PROCESS-CONTROL OF 90Y INCORPORATION DURING OCTREOTHERTM PRODUCTION.       01WGO01R
         APPROPRIATE OR INAPPROPRIATE

   3     OCTREOTHER CONSISTENCY RUNS STABILITY STUDY                                   05WGO00R

   4     MEASUREMENT OF YTTRIUM (90Y) BREMMSSTRAHLUNG                                  03MJ098R

   5     Water content in OctreoTher reaction mixture.                             03mpa02R (version
         Validation of the method.                                                     2) + memo

   6     Stability of NaCl 0.9% purged with Nitrogen for OctreoTher production         04mpa01r

   7     Quality testing of Reaction Mixture for OctreoTher PO: 70190                  05mjo03R

   8     Stability of NaCl 0.9% purged with Nitrogen for OctreoTher production.
         FM 257 stopper vs. FM 259 Stopper                                             05mpa02r

   9     OctreoTher consistency runs. Stability Study.                                 05wgo00r

  10     Scale up production process OctreoTher Novartis B220x clinical studies        06evw02r

  11     STABILITY STUDY OCTREOTHERTM REACTION MIXTURES INTERIM REPORT                 06WGO00R

  12     Annual Overview OctreoTherTM Productions 2003                                 07mjo04r

  13     Bone marrow dosimetry consequences by widening the specification for
         free 90Y in therapy with OctreoTher                                           07MKO00R

  14     JUSTIFICATION FOR THE OF ACID INTRODUCTION OF ASCORBIC ACID IN THE
         FORMULATION OF OCTREOTHER BULKSOLUTION                                        08MJO02R

  15     PRODUCTION AND QUALITY CONTROL OF SMT487                                      08MJO97R
         FORMULATION FOR USE IN THE SUB-ACUTE TOXICITY STUDY

  16     PRODUCTION AND QUALITY CONTROL OF SMT487 FORMULATION FOR USE IN THE
         ACUTE TOXICITY STUDY                                                          09MJ097R

  17     Feasibility of heat sterilization of Octreother (Y90)                         09MJ098R

  18     OCTREOTHER CONSISTENCY RUNS and STABILITY STUDY OF VIALS CONTAINING
         3330 RESPECTIVELY 4440 MBq Y-90 OCTREOTHER                                    09WGO01R

  19     Overview OctreoTher(TM) productions 2002                                      10ewe03r

  20     Stability Study OctreoTher Reaction Mixtures                                  11mjo02r

  21     Annual Overview OctreoTher(TM) Productions 2004                               10mjo05r

  22     Non-radioactive Testing of OctreoTher Production Process in the
         Hot Liquid Facility                                                           12mjo99r

  23     OCTREOTHER CONSISTENCY RUNS OF ADAPTED PRODUCTION PROCESS.
         STABILITY STUDY                                                               14WGO00R

  24     Identification of an impurity visible in HPLC analysis of Yttrium
         labelled DOTA-Tyr3-octreotide                                                 16MJ098R

  25     DETERMINATION OF EXCIPIENTS IN REACTION VIALS FOR OCTREOTHER
         VALIDATION OF THE METHOD                                                      17MJO97R
</TABLE>

                                       18

<PAGE>

<TABLE>
<S>      <C>                                                                       <C>
  26     Integrity testing of container/closure system to be used in the
         Octreother hot liquid production                                              17MJO99R

  27     DETERMINATION OF EXCIPIENTS IN REACTION VIALS FOR OCTREOTHER
         VALIDATION OF THE METHOD Addendum                                             19MJO00R

  28     OCTREOTHER CONSISTENCY RUNS OF ADAPTED PRODUCTION PROCESS.
         MICROBIOLOGICAL DATA                                                          24WGO00R

  29     Preliminary Stability Results SMT487 (90Y) Liquid                             27mjo97r

  30     Radiochemical Purity Determination of OctreoTher Using Different
         Integration Events                                                            32MJ099R

  31     OCTREOTHER FORMULATION REPORT                                               5061/14/1996

  32     DEVELOPMENT OF OCTREOTHER-90 KIT                                            5061/15/1995

  33     DOTA-TYR3-OCTREOTIDE ASSAY BY HPLC.
         VALIDATION OF METHOD                                                        5061/21/1996

  34     RADIOCHEMICAL PURITY OF 90Y-DOTA-TYR3-OCTREOTIDE.
         VALIDATION OF THE METHOD                                                    5061/22/1996

  35     INCORPORATION OF 90Y-DOTA-TYR3-OCTREOTIDE VALIDATION OF THE METHOD          5061/24/1996

  36     STABILITY 90Y-SMT487 FOR HOT-TOXICITY STUDY                                   07MJO97R

  37     Quality testing of Yttrium (90Y) chloride by means of incorporation
         assay into DOTA-Tyr3-Octreotide                                               12mjo02R

  38     Influence of the Alltech 1.0 ml Minivial 20/4000 on the incorporation
         capability of Y-90 to SMT 487 peptide                                         18ewe03r

  39     Close out report B220X project, validation status of OctreoTher
         facility                                                                     2465201001

  40     Extension of the OctreoTher production                                    Memo to File, E.
                                                                                     van Wensveen

  41     Identification of Impurities in gentisic acid and peroxide cured
         silicon tubing                                                                13MJO02R

  42     Air-tightness testing mepal container for Yttrium-OctreoTher
         solution shipments                                                           2132701003

  43     testing box 33 Multipack containing Yttrium-OctreoTher solution              2132701001
</TABLE>

                                       19

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Octreother                                                                 D3-03925
Reactionmixture for Octreother bulk                                        D6-03925
Reactiemixture for Octreother                                              D7-03925
Dispensing set, solutions and dilutions, 10 - 25 ml, sterilized            E2-10504
Fiterset, Millipak 60, sterilized                                          E2-10561
tubingset Octreother, cel 0902.000 Compudil A, sterilized                  E2-11326
tubingset Octreother, cel 0902.000 diluter, sterilized                     E2-11328
tubingset Octreother, cel 0903.000, sterilized                             E2-11331
Filter, Pall, NOVASIP, C2PFRP1,                                            E2-11375
Tubingset, diluter Octreother, 3 flasks, sterilized                        E2-11407
tubingset, verdunner Octreother, sterilized                                E2-11412
Pumping set Octreother, cel 0903.000                                       E2-11413
Needle, pencilpoint, diam 1,2mm                                            E2-11418
Z-needle, pencilpoint, lengte 20x20x78mm                                   E2-11419
Curved needle, pencilpoint, diam 1,2mm, lengte 20x54mm                     E2-11421
Tubing set, bulkfluidreactionmixture, sterile                              E2-11441
Curved needle,pencilpoint, diam 1,2 mm, lengte 20x87 mm                    E2-11445
Curved needle,pencilpoint, diam 1,2 mm, lengte 28x57 mm                    E2-11446
Z-needle, pencilpoint, 20x20x78mm, passivated                              E2-11447
Curved needle, pencilpoint, 20x54mm, passivated                            E2-11448
Curved needle,pencilpoint, diam 1,2 mm, lengte 20x50 mm                    E2-11449
Dispensing set, sofiumchloride for octreother, gesteriliseerd              E2-11450
Curved needle, pencilpoint, 28x57mm, gepassiveerd                          E2-11456
Curved needle, pencilpoint, 20x87mm, gepassiveerd                          E2-11457
Dispensing set Octreother forunit cel 0903.000, gesteriliseerd             E2-11467
Filterset A Millipak 60, Pt-netted tubing                                  E2-11490
filterset B Millipak 60, Pt-netted tubing                                  E2-11491
Dispensing set, Pt-netted tubing                                           E2-11492
dispensingset, Pt-netted tubing                                            E2-11492
flask 2, assembleerd, Millipak 60, Pt-netted tubing                        E2-11493
flask 2, assembleerd, Millipak 60, Pt-netted tubing                        E2-11493
Dispensing set for kits, Pt-netted tubing                                  E2-12007
Lyophilization vial 10 ml, stopper FM157, clean                            E2-12198
Wing needle, diam 2,0mm,  lengte 20x280mm                                  E2-12336
transportcontainer Octreother                                              E3-11472
Certificate of analysis: Octreother                                        E4-11335
SPC Yttrium (Y90) SMT487, i.v.                                             E4-11373
Rubberstopper                                                              E6-10030
Rubberstopper                                                              N6-10856
Water for injecties, in bulk                                               E5-10114
Purified water                                                             E5-12300
Materials for the productie of octreother                                  E5-11408
Lyophilization vial 10 ml,                                                 E6-10009
Lyophilization stopper, DIAM 20 mm,  FM157,                                E6-10018
vial 100 ml, clean gesteriliseerd                                          E6-11303
vial 100ml, filled with nitrogen                                           E6-11304
Rubberstop, diam 32 mm, FM257, clean, sterile                              E6-11308
Needleprotector, rubber, 14 mm                                             E6-11394
Elution needle protector                                                   E6-10130
Octreother                                                                 F3-03925
Reactiemixture for octreother, bulk                                        F6-03925
</TABLE>

                                       20

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Reactiemixture for voor Octreother                                         F7-03925
ring glassvial Octreother-Lab                                              G0-00095
ring Nensure P-2 flacon Octreotherlab                                      G0-00102
ring 10 ml lyophilization vial Octreotherlab                               G0-00105
ring for 100 ml flacon octreotherlab                                       G0-00114
Testset for visual inspection of vials in octreotherlab en radiopharmacy   G0-00147
Vial 500 ml Vacuum steriel                                                 N1-12015
Tubing, siliconubber, diam 6,0 x 10,0 mm                                   N2-10044
Tubing, siliconrubber, diam 4,0x7,0mm                                      N2-10459
Tubing, siliconrubber, diam 4,0 x 7,0 mm                                   N2-10459
Tubing, siliconrubber, diam 1,0x3,0mm                                      N2-10460
Filter millex                                                              N2-10825
Tubing, siliconrubber, diam 4,0 x 10,0 mm                                  N2-10462
Injection needle 18G, lengte 19 mm                                         N2-10561
Filter millipore, millipak 60 MPGL 06GH2                                   N2-10811
Filter hydrofoob ACRO 50                                                   N2-10826
Vail 250 ml                                                                N2-11429
Tubing, siliconrubber, 1,6 x 6,4 mm                                        N2-11435
Tubing, siliconrubber, 3,2 x 8,0 mm                                        N2-11436
Tubing 1,02 mm, diam  2,69 mm, lengte 3 m                                  N2-11476
Filter, Whatman, Polycap 36 SPF                                            N2-11508
Double tubingsett, 3,2 mm                                                  N2-11515
Double tubingset, 4,8 mm                                                   N2-11516
Curved needle, diam 0,9 x 1,2 mm, lengte 20 x 200 mm                       N2-11595
Threeway valve                                                             N2-11730
Tubing, siliconrubber, 2,38 x 4,0 mm                                       N2-11743
Tubing siliconrubber, 2,29x0,85x900mm                                      N2-11744
capsule, diam 32,5 mm,                                                     N2-11745
Filter, Pall, Novasip, C2PFRP1                                             N2-11775
Tubing, siliconrubber, diam. 1,6 x 4,8 mm                                  N2-11785
Vial 500ml                                                                 N2-11820
dispensingset octreother, cel 0903.000                                     N2-11852
Filter, Millex 0,22 ugm, SLGP 033 RS                                       N2-11855
Tubing, siliconrubber, diam 4,8 x 9,6 mm                                   N2-11858
Tubing, siliconrubber, diam 6,4 x 9,6 mm                                   N2-11859
Syringe                                                                    N2-11925
Tubing, PTFE, capilaire tubing                                             N2-11926
Wing needle, 18G x 1,5                                                     N2-11927
Syringe 1 ml luerlock H804                                                 N2-12035
Neo labbinders                                                             N2-12041
Tubing siliconenrubber 10 x 14                                             N2-12075
T-piece Diam, 6 MM P.P.                                                    N2-12081
Filter Millex SLFG 025 LS                                                  N2-12098
Connector Luer 0,8 female                                                  N2-12111
Connector Luer 1.6 male                                                    N2-12112
Connector luer 0,8 male                                                    N2-12113
Connector Luer 1,6 female                                                  N2-12115
Connector luer 3.2 Female                                                  N2-12117
Connector Luer 3.2 MALE                                                    N2-12118
Naald vleugel/beluchting 1.6 MM                                            N2-12119
T-part, polupropylene                                                      N2-11915
Beaker, plastic                                                            N3-11854
</TABLE>

                                       21

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Demineralized water                                                        N5-70362
Ascorbic acid                                                              N5-70001
sodiumhydroxide,                                                           N5-70016
nitrogenf 99,98 % fluid                                                    N5-70120
GENTISIc acid                                                              N5-70128
Inositol                                                                   N5-70135
Water forr injections in vial, 1000 ml                                     N5-70261
sodiumchloride-solution 0,9% in vial 1000 ml                               N5-70267
DOTA-TYR3-octreotide                                                       N5-70415
Connector                                                                  N6-10158
lyophilizationstopper diam 20mm grey FM157                                 N6-10159
Needle, Z-vormig UTK                                                       N6-10177
Venapunction needle                                                        N6-10179
Lyophilization vial 10 ml                                                  N6-10217
Needle steel 316, diam 0,83x1,2mm, lengte 173mm                            N6-10247
Elution needle protector                                                   N6-10006
vail 100 ml,                                                               N6-11736
Rubberstopper, diam 32 mm, , FM257                                         N6-11737
capsule, aluminium, diam 20 mm                                             N6-11884
capsule, diam 32,5 mm,                                                     N6-11887
Yttrium chloride (Y90)                                                     N7-70429
Needle                                                                     N6-10248
Tubing set                                                                 P5-11407
dispensinglset, solutions, 10 - 25 ml, gesteriliseerd                      P2-10504
Filterrset, Millipak 60, gesteriliseerd                                    P2-10561
tubingset Octreother, cel 0902.000, Compudil A, gesteriliseerd             P2-11326
tubingset Octreother, cel 0902.000, diluter, gesteriliseerd                P2-11328
tubingset Octreother, cel 0903.000, gesteriliseerd                         P2-11331
tubingset, diluter octreother, 3 flasks, gesteriliseerd                    P2-11407
Tubingset diluetr octreother, gesteriliseerd                               P2-11412
Pumptubingset octreother, cel 0903.000                                     P2-11413
tubingset, bulk reactionmixture octreother, gesteriliseerd                 P2-11441
Z-needle, pencilpoint, 20x20x78mm, gepassiveerd                            P2-11447
Curved needle, pencilpoint, 20x54mm, gepassiveerd                          P2-11448
dispensingset sodiumchloride for octreother gesteriliseerd                 P2-11450
Curved needle, pencilpoint, 28x57mm, gepassiveerd                          P2-11456
Curved needle, pencilpoint, 20x87mm, gepassiveerd                          P2-11457
Materials for the production of octreother                                 P5-11408
Lyophilization stopper, DIAM 20 mm,  FM157,sterilized                      P6-10018
vial 100ml filled with nitrogen                                            P6-11304
Rubberstop, diam 32 mm, , FM257,                                           P6-11308
Visual inspection of octreother vials                                      W0-10364
Procedure to calculate the yttrium-90 amount to order                      W0-10436
Measurement of  radioactivity with an ionisatiecahmber with picoammeter    W1-10001
</TABLE>

                                       22

<PAGE>

                    TABLE 3. REGULATORY INFORMATION DOCUMENTS

<TABLE>
<CAPTION>
Number   Title
------   -----
<S>      <C>
  1      Yttrium (90Y) SMT 487 Clinical Trial Application Information
         Chemical and Pharmaceutical Data

  2      Yttrium (90Y) SMT 487 IND Information
         Manufacturing Description
</TABLE>

                                       23

<PAGE>

                          TABLE 4. ADDITIONAL DOCUMENTS

<TABLE>
<CAPTION>
Number   Title
------   -----
<S>      <C>
  1      Description of the lyophilization process

  2      Description of the equipment used in the manufacturing process
         for the Product

  3      Description of the Quality Control equipment used in the
         quality control methods of the Vials

  4      Description of the Quality Control equipment used in the
         quality controls methods of the Product
</TABLE>

                                       24

<PAGE>

B.2. Manufacture and Quality Control of the Vials (OctreoTher Reaction Vial)

Prior to commencing the manufacturing and quality control technology transfer at
the Petten Facility, MIP personnel must successfully complete Laboratory and
Radiation Safety Training conducted by Safety Personnel at the MALLINCKRODT
Petten site.

     B.2.1. Manufacturing of the Vials

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
manufacturing process for the OctreoTher Reaction Vial consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands. The
following services will be provided:

     -    a review of the Process Flow Sheet describing the manufacturing,
          ingredients, and materials needed in the manufacturing process;

     -    a review of the packaging;

     -    one demonstration of the preparation of the matrix solution, without
          the addition of the peptide SMT 487, by MALLINCKRODT personnel during
          the initial visit to Petten by MIP personnel. MIP has the right to
          request that MALLINCKRODT personnel perform one additional
          demonstration of the preparation of the matrix solution, without the
          addition of the peptide SMT 487, at a date and site to be determined
          after the initial visit to Petten by MIP personnel. In the event that
          this additional demonstration occurs, MIP shall pay MALLINKRODT'S
          expenses pursuant to Section 2.3;

     -    at least one but not more than two preparations of the matrix solution
          by MIP personnel with MALLINCKRODT personnel supervision during the
          initial visit to Petten by MIP personnel. MIP has the right to perform
          at least one but not more than two preparations of the matrix solution
          by MIP personnel with MALLINCKRODT

                                       25

<PAGE>

          personnel supervision at a date and site to be determined after the
          initial visit to Petten by MIP personnel. In the event that such
          additional activities occur, MIP shall pay MALLINKRODT'S expenses
          pursuant to Section 2.3;

     -    the parameters for the lyophilization cycle;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to the OctreoTher Reaction Vial manufacturing, such as product
          specifications, batch records, stability studies, fill-finish, and the
          lyophilization cycle.

     B.2.2. Quality Control of Vials

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
quality control (QC) methods for the OctreoTher Reaction Vial consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands.
OctreoTher Reaction Vials from lot number 220930 will be used for this testing.
The following services will be provided:

     -    one demonstration of the QC methods for the ingredients by
          MALLINCKRODT personnel during the initial visit to Petten by MIP
          personnel. MIP has the right to request that MALLINCKRODT personnel
          perform one additional demonstration of the QC methods at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that this additional demonstration occurs, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    one demonstration of in-process testing by MALLINCKRODT personnel
          during the initial visit to Petten by MIP personnel. MIP has the right
          to request that MALLINCKRODT personnel perform one additional
          demonstration of in-process testing at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that this additional demonstration occurs, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

                                       26
<PAGE>

     -    one demonstration of the QC methods for the Vial by MALLINCKRODT
          personnel during the initial visit to Petten by MIP personnel. MIP has
          the right to request that MALLINCKRODT personnel perform one
          additional demonstration of the QC methods for the Vial at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that this additional demonstration occurs, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    at least one but not more than two completions by MIP personnel of the
          QC methods for the ingredients, in-process testing, and the Vial with
          MALLINCKRODT personnel supervision during the initial visit to Petten
          by MIP personnel. MIP has the right to perform at least one but not
          more than two completions of the QC methods for the ingredients,
          in-process testing, and the Vial with MALLINCKRODT personnel
          supervision at a date and site to be determined after the initial
          visit to Petten by MIP personnel. In the event that such additional
          activities occur, MIP shall pay MALLINKRODT'S expenses pursuant to
          Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to OctreoTher Reaction Vial quality control.

B.3. Manufacture and Quality Control of the Product (OctreoTher Hot Liquid)

     B.3.1. Manufacturing of the Product

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
manufacturing process for the Product consistent with or equivalent to GMPs at
the MALLINCKRODT facility in Petten, The Netherlands. OctreoTher Reaction Vials
from lot number 220930 will be used for the manufacturing of the Product. The
following services will be provided:

                                       27

<PAGE>

     -    a review of the Process Flow Sheet describing the manufacturing,
          ingredients, and materials needed in the manufacturing process;

     -    a review of the packaging;

     -    one demonstration of the preparation of the OctreoTher Hot Liquid
          without Y-90 by MALLINCKRODT personnel during the initial visit to
          Petten by MIP personnel. MIP has the right to request that
          MALLINCKRODT personnel perform one demonstration of the OctreoTher Hot
          Liquid without Y-90 at a date and site to be determined after the
          initial visit to Petten by MIP personnel. In the event that this
          additional demonstration occurs, MIP shall pay MALLINKRODT'S expenses
          pursuant to Section 2.3;

     -    one demonstration of the preparation of the OctreoTher Hot Liquid with
          Y-90 by MALLINCKRODT personnel during the initial visit to Petten by
          MIP personnel. MIP has the right to request that MALLINCKRODT
          personnel perform one additional demonstration of the OctreoTher Hot
          Liquid with Y-90 at a date and site to be determined after the initial
          visit to Petten by MIP personnel. In the event that this additional
          demonstrations occur, MIP shall pay MALLINKRODT'S expenses pursuant to
          Section 2.3;

     -    one preparation of the OctreoTher Hot Liquid without Y-90 by MIP
          personnel with MALLINCKRODT personnel supervision during the initial
          visit to Petten by MIP personnel. MIP has the right to perform one
          preparation of the OctreoTher Hot Liquid without Y-90 by MIP personnel
          with MALLINCKRODT personnel supervision at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that such additional activities occur, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

                                       28

<PAGE>

     -    one preparation of the OctreoTher Hot Liquid with Y-90 by MIP
          personnel with MALLINCKRODT personnel supervision during the initial
          visit to Petten by MIP personnel. MIP has the right to perform one
          preparation of the OctreoTher Hot Liquid with Y-90 by MIP personnel
          with MALLINCKRODT personnel supervision at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that such additional demonstrations occur, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to the OctreoTher Hot Liquid manufacturing, such as product
          specifications, batch records, and stability studies.

     B.3.2. Quality Control of Product

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
quality control (QC) methods for the OctreoTher Hot Liquid consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands. The
following services will be provided:

     -    one demonstration of in-process testing by MALLINCKRODT personnel
          during the initial visit to Petten by MIP personnel. MIP has the right
          to request that MALLINCKRODT personnel perform one additional
          demonstration of in-process testing at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that this additional demonstration occurs, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

     -    one demonstration of the QC methods for the Product by MALLINCKRODT
          personnel, preferably on the Product manufactured by MALLINCKRODT in
          Section B.3.1 during the initial visit to Petten by MIP personnel. MIP
          has the right to request

                                       29

<PAGE>

          that MALLINCKRODT personnel perform one additional demonstration of
          the QC methods for the Product at a date and site to be determined
          after the initial visit to Petten by MIP personnel. In the event that
          this additional demonstration occurs, MIP shall pay MALLINKRODT'S
          expenses pursuant to Section 2.3;

     -    at least one but not more than two completions by MIP personnel of the
          QC methods for in-process testing and the Product, preferably on the
          Product produced by MIP in Section B.3.1, with MALLINCKRODT personnel
          supervision during the initial visit to Petten by MIP personnel. MIP
          has the right to perform at least one but not more than two
          completions by MIP personnel of the QC methods for in-process testing
          and the Product with MALLINCKRODT personnel supervision at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that such additional activities occur, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to OctreoTher Hot Liquid quality control.

B.4. Response to Inquires Concerning the Technology

MALLINCKRODT personnel will be available to provide responses or clarification
to inquiries from MIP concerning the Technology during the course of the
transfer of the Technology as described in Section 2.3.

B.5. Equivalency Testing of the Product (OctreoTher Hot Liquid)

MALLINCKRODT and MIP personnel will conduct equivalency testing on the
OctreoTher Hot Liquid. Equivalency testing will consist of MALLINCKRODT and MIP
independently conducting quality control (QC) testing of the Product as defined
by the specifications in Section

                                       30

<PAGE>

5.3.1 of the Yttrium ((90)Y) SMT 487 IND Information Manufacturing Description
attached to this Agreement as EXHIBIT F. The OctreoTher Hot Liquid will be
manufactured consistent with or equivalent to GMPs by either MALLINCKRODT or MIP
as specified below. The following services will be provided:

     -    MALLINCKRODT will prepare one manufacturing preparation of the
          OctreoTher Hot Liquid sufficient to provide finished Product for QC
          testing by both MALLINCKRODT and MIP;

     -    MALLINCKRODT will ship to MIP the required vials of Product necessary
          to perform the QC testing;

     -    On the same date, MALLINCKRODT and MIP will independently perform the
          QC tests and MALLINCKRODT will inform MIP of its results.

     -    MALLINCKRODT will receive from MIP one but not more than two
          manufacturing preparations of the OctreoTher Hot Liquid manufactured
          by MIP;

     -    On the same date, MALLINCKRODT and MIP will independently perform the
          QC tests and MALLINCKRODT will inform MIP of its results.

                                       31
<PAGE>

                                    EXHIBIT C

               CERTIFICATION OF COMPLETION OF TECHNOLOGY TRANSFER

MALLINCKRODT INC. hereby certifies that it has completed its Technology transfer
obligations under that certain Agreement, dated as of ____________, 2006,
between MALLINCKRODT INC. and MOLECULAR INSIGHT PHARMACEUTICALS, INC.

MALLINCKRODT INC.

By:
    ---------------------------------
Title:
       ------------------------------
Date:
      -------------------------------

                                       32

<PAGE>

                                    EXHIBIT D

Specifications for the OctreoTher SMT 487 Reaction Vial are as follows:

<TABLE>
<CAPTION>
            TEST                               LIMIT
            ----                               -----
<S>                            <C>
Appearance                     clear and no visual impurities
pH                             4.0 - 5.0
Sterility                      sterile
Endotoxins                     < or = 20 EU/vial
Ascorbic acid                  64.0 - 78.2 mg/vial
Inositol                       36.0 - 44.0 mg/vial
Radiochemical purity, 15 min   > or = 90%
Radiochemical purity, 6 h      > or = 90%
(90)Y-Incorporation            > or = 99.5%
SMT 487                        72.0 - 88.0 ug/vial
Uniformity SMT 487 content     10 vials within 85 - 115% (n=10) or
                               < or = 1 of 30 out of 85 - 115%, but all
                               within 75 - 125%
Gentisic acid                  14.4 - 17.6 mg/vial
Water content                  < or = 5%
Identity                       comply with test
</TABLE>

                                       33

<PAGE>

                                    EXHIBIT E

The overall work plan and timeline for the Transfer of Technology is as follows:

<TABLE>
<CAPTION>
                                                                 Month 1   Month 2   Month 3    Month 4    Month 5     Month 6
                                                                   Days      Days      Days      Days        Days        Days
TASK NAME                                                         1 - 30   31 - 60   61 - 90   91 - 120   121 - 150   151 - 180
---------                                                        -------   -------   -------   --------   ---------   ---------
<S>                                                              <C>       <C>       <C>       <C>        <C>         <C>
CONTRACT EXECUTION
   Mallinckrodt & MIP Execute Contract
   Mallinckrodt Receives Initial Payment at Contract Execution
   Mallinckrodt Invoices MIP and Receives 50% Payment for
      OctreoTher Vials
   Mallinckrodt Initiates SOP Translation per MIP Instructions
COMMENCEMENT OF TECHNOLOGY TRANSFER
   Mallinckrodt Transmits R&D and Regulatory Documents to MIP
   Mallinckrodt Transmits First Set of Translated SOPs to MIP
   Mallinckrodt Invoices MIP for Payment due upon Commencement
      of Technology transfer
   Mallinckrodt Ships OctreoTher Vials to MIP per Their
      Instructions
   Mallinckrodt Invoices MIP for Remaining 50% Payment due for
      OctreoTher Vials
   Mallinckrodt Receives Above Two Payments Prior to On-Site
      Technology Transfer
TRANSFER OF TECHNOLOGY AT MALLINCKRODT PETTEN FACILITY
   Mallinckrodt Provides Services per Exhibit B
MALLINCKRODT TECHNICAL AVAILABILITY
   Mallinckrodt Provides Services per Exhibit B
TRANSFER OF TECHNOLOGY AT MIP DESIGNATED FACILITY (IF
   REQUESTED)
   Mallinckrodt Provides Services per Exhibit B
EQUIVALENCY TESTING
   Mallinckrodt Provides Services per Exhibit B
TECHNOLOGY TRANSFER COMPLETION
   Mallinckrodt Sign-Off of Certificate of Completion
   Mallinckrodt Invoices for and Receives Payment for
      Completion of Technology Transfer
</TABLE>

                                       34

<PAGE>

                                    EXHIBIT F

Specifications for Yttrium (90Y) SMT 487 (OctreoTher Hot Liquid) are as follows:

<TABLE>
<CAPTION>
           TEST                                  LIMIT
           ----                                  -----
<S>                         <C>
Appearance                  Clear, colourless, or slightly yellow solution
(90)Y-Incorporation         > or = 99.3%
Radiochemical purity        > or = 90%
Radioactive concentration   51.6 Bq/ml +/- 10% (1.4 mCi/ml +/- 10%)
pH                          4.0 - 5.0
Endotoxins                  < or = 0.2 EU/vial (parametric release)
Sterility                   sterile (parametric release)
</TABLE>

                                       35

<PAGE>

                                    EXHIBIT G

Below is a list of MALLINCKRODT competitors.

     Bracco
     Bristol-Myers Squibb
     Cardinal Health, Inc.
     GE Healthcare Division of the General Electric Company
     Schering AG

                                       36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]